Welcome to our dedicated page for Mountain Vy Md news (Ticker: MVMDF), a resource for investors and traders seeking the latest updates and insights on Mountain Vy Md stock.
Mountain Valley MD Holdings Inc. (MVMDF) features regularly in corporate news for its progress across three stated business lines: nutraceuticals using its patented Quicksome™ oral formulation technology, husbandry animal and aquatic applications based on its Quicksol™ solubility platform, and agricultural initiatives centered on the licensed Agrarius™ plant signaling technology. Company updates often detail commercialization milestones, licensing agreements, and field trial results.
News releases describe how Mountain Valley MD works with a U.S.-based GMP manufacturing partner to produce Quicksome™-powered sublingual nutraceutical products for licensees and for its proprietary “Mountains Of…” brand. Coverage includes product launches and formulation work for categories such as sleep, energy, immunity, stress and anxiety support, and other wellness-focused applications.
In agriculture, the company’s news flow highlights its exclusive license to sell Agrarius™ across North America, Mexico, Central America, South America, and the Caribbean, along with extensive crop trials and a Performance Guarantee Program under which clients pay only if defined yield or plant health thresholds are met. Updates frequently summarize trial outcomes in crops like citrus, corn, sugarcane, soybeans, potatoes, cotton, and pasture grass, as well as regulatory and registration progress in various jurisdictions.
For husbandry animals and aquatic species, Mountain Valley MD reports on the development and licensing of Soluvec™ 1%, a Quicksol™-based ivermectin formulation, including agreements with partners such as a Bangladesh licensee. Investors and observers can use this news page to follow the company’s reported commercialization steps, partnership developments, and technology validation efforts over time.
Mountain Valley MD Holdings Inc. (CSE: MVMD, OTCQB: MVMDF) announced positive results from a controlled cold chain evaluation of its Quicksome™ liposome technology for preserving the Trivalent Inactivated Poliovirus Vaccine (tIPV). IPV serotype two showed 100% preservation at 40°C for five days, surpassing WHO guidelines, while serotypes one and three achieved 50% preservation. The company aims to enhance this technology to achieve full compliance for all serotypes. Mountain Valley MD also signed a two-year research agreement with the FDA to further develop its cold chain technology.
Mountain Valley MD Holdings Inc. (MVMD) has announced significant advancements, including the approval of a patent for its Water Dissolvable Macrocyclic Lactone Cyclodextrin Complexes. This patent allows MVMD to enhance its solubilization technology, crucial for applications in human and animal health.
In partnership with a GMP production entity, MVMD's Ivectosol™ showed high yield in initial trials. Additionally, a collaboration with the FDA on a cold chain project aims to preserve vaccines under extreme conditions. MVMD also progresses in pre-clinical trials for cancers and tuberculosis, while exploring cannabis product formulations.
Mountain Valley MD Holdings Inc. (CSE: MVMD) has announced promising results from its BSL-4 lab COVID-19 study involving its solubilized Ivermectin technology, Ivectosol™. The study demonstrated that a dose of 2.5 mg/kg effectively cleared the B.1.1.7 variant, with in vitro tests confirming antiviral activity against other variants. The company is now advancing to phase one human trials focusing on efficacy and safety of Ivectosol™ sublingual wafers. The breakthrough study marks a significant validation of Ivectosol™ in combating COVID-19 variants.
Mountain Valley MD Holdings Inc. (MVMDF) has announced the filing of a novel cancer adjuvant patent and the initiation of pre-clinical trials for Ivectosol™ targeting triple-negative breast cancer, metastatic melanoma, and lung carcinoma. The company aims to leverage the anti-cancer properties of ivermectin, demonstrated in previous studies, to enhance current chemotherapy and immunotherapy protocols. The first results from these trials are anticipated by the end of June 2021.
Mountain Valley MD Holdings Inc. (MVMD) is set to transition from the OTC Pink Sheets to the OTCQB Venture Marketplace on February 16, 2021, trading under the symbol MVMDF. This move is aimed at enhancing visibility and accessibility for U.S. investors, allowing for broader participation in the company's growth. The OTCQB Market is recognized for early-stage companies and offers improved trading experiences, aligning with MVMD's goal of increasing share liquidity. The company is focused on innovative drug delivery technologies in the health and wellness sectors.